Co-Diagnostics, Inc.
CODXNASDAQHealthcare● Active
$5.05
$-0.58(-10.30%)
Market Cap$5637042
P/E Ratio—
52W High$46.5
52W Low$1.26
Co-Diagnostics, Inc. (CODX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CODX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$4.06
Est. -$3.75 · -8.3%
Revenue
$0.00B
Est. $0.00B · +14.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CODX reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$3.00 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$3.75 | -$4.06 | -8.3% | $0.00B | $0.00B | +14.9% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$3.60 | -$16.35 | -354.2% | $0.00B | $0.00B | +108.5% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$5.71 | -$4.80 | +15.9% | $0.00B | $0.00B | +15.4% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.25 | -$0.23 | +8.0% | $0.00B | $0.00B | -45.7% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.33 | -$0.24 | +27.3% | $0.00B | $0.00B | -73.2% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.34 | -$0.36 | -5.9% | $0.00B | $0.00B | -60.2% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.33 | -$0.32 | +3.0% | $0.00B | $0.00B | +71.0% |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$3.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$4.06
EPS Est.
-$3.75
EPS Surpr.
-8.3%
Revenue
$0.00B
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$16.35
EPS Est.
-$3.60
EPS Surpr.
-354.2%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$4.80
EPS Est.
-$5.71
EPS Surpr.
+15.9%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.23
EPS Est.
-$0.25
EPS Surpr.
+8.0%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.33
EPS Surpr.
+27.3%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.34
EPS Surpr.
-5.9%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.32
EPS Est.
-$0.33
EPS Surpr.
+3.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $4.80 | $4.80 | $4.80 | 1 |
| Q3 FY2028 | $4.81 | $4.81 | $4.81 | 1 |
| Q2 FY2028 | $4.91 | $4.91 | $4.91 | 1 |
| Q1 FY2028 | $4.73 | $4.73 | $4.73 | 1 |
| Q4 FY2027 | $-1.22 | $-1.22 | $-1.22 | 1 |
| Q3 FY2027 | $-0.98 | $-0.98 | $-0.98 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -8.3% | $1.60 | $1.63 | +1.87% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -354.2% | $1.70 | $1.86 | +9.41% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +15.9% | $11.88 | $11.16 | -6.06% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +8.0% | $7.89 | $7.95 | +0.76% |
| ▲ Q2 FY2025 | May 8, 2025 | +27.3% | $10.50 | $10.65 | +1.43% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -5.9% | $12.51 | $11.76 | -6.00% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +3.0% | $36.30 | $35.40 | -2.48% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +26.5% | $32.10 | $30.60 | -4.67% |
Q2 FY2026+1.87%
Report Date
May 14, 2026
EPS Beat/Miss
-8.3%
Price Before
$1.60
Price After
$1.63
Q1 FY2026+9.41%
Report Date
Mar 31, 2026
EPS Beat/Miss
-354.2%
Price Before
$1.70
Price After
$1.86
Q4 FY2025-6.06%
Report Date
Nov 13, 2025
EPS Beat/Miss
+15.9%
Price Before
$11.88
Price After
$11.16
Q3 FY2025+0.76%
Report Date
Aug 14, 2025
EPS Beat/Miss
+8.0%
Price Before
$7.89
Price After
$7.95
Q2 FY2025+1.43%
Report Date
May 8, 2025
EPS Beat/Miss
+27.3%
Price Before
$10.50
Price After
$10.65
Q1 FY2025-6.00%
Report Date
Mar 27, 2025
EPS Beat/Miss
-5.9%
Price Before
$12.51
Price After
$11.76
Q4 FY2024-2.48%
Report Date
Nov 7, 2024
EPS Beat/Miss
+3.0%
Price Before
$36.30
Price After
$35.40
Q3 FY2024-4.67%
Report Date
Aug 8, 2024
EPS Beat/Miss
+26.5%
Price Before
$32.10
Price After
$30.60
Avg Beat Reaction-2.20%
Avg Miss Reaction+1.76%
Beat Rate5 / 8 quarters
Largest Move+9.41% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CODX ends December
Co-Diagnostics, Inc. (CODX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-4.06 — missing the analyst consensus of $-3.75 by -8.3%. The next CODX earnings date is expected around September 1, 2026.
Each quarter, investors track CODX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CODX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CODX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CODX earnings · 5 questionsCo-Diagnostics, Inc.'s next earnings report is expected around September 1, 2026. CODX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CODX historically reports after market close (AMC).
CODX earnings datewhen is CODX earningsCODX next earnings datewhen does CODX report earningsCODX earnings calendar
▸ Source: FMP · Co-Diagnostics, Inc. SEC filings · US GAAP · Co-Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026